Mario Mutuleanu received his MSc from the University of Medicine and Pharmacy “Carol Davila” in 2018 and then started the Ph.D. studies at the same university in 2020, studying the effects on diagnosis, treatment, and patient follow-up of oncological patients when performing quantitative analysis of the data obtained through molecular imaging techniques. Since 2019, he is a nuclear medicine resident physician in the Department of Nuclear Medicine at the Institute of Oncology “Prof. Dr. Alexandru Trestioreanu” Bucharest. Dr. Mutuleanu’s research interests involve bone metastases diagnosis, better differentiation between metastatic lesions and other lesions and patient disease staging, treatment, and follow-up. More focus is given to the implication of quantitative analysis of molecular imaging data on differentiating between metastatic lesions and other lesions that can be present in oncological patients.
Current position: Nuclear medicine resident physician in the Department of Nuclear Medicine at the Institute of Oncology “Prof.Dr.Alexandru Trestioreanu” Bucharest.
Mario Mutuleanu received his MSc from the University of Medicine and Pharmacy “Carol Davila” in 2018 and then started the Ph.D. studies at the same university in 2020, studying the effects on diagnosis, treatment, and patient follow-up of oncological patients when performing quantitative analysis of the data obtained through molecular imaging techniques. Since 2019, he is a nuclear medicine resident physician in the Department of Nuclear Medicine at the Institute of Oncology “Prof. Dr. Alexandru Trestioreanu” Bucharest. Dr. Mutuleanu’s research interests involve bone metastases diagnosis, better differentiation between metastatic lesions and other lesions and patient disease staging, treatment, and follow-up. More focus is given to the implication of quantitative analysis of molecular imaging data on differentiating between metastatic lesions and other lesions that can be present in oncological patients.
Current position: Nuclear medicine resident physician in the Department of Nuclear Medicine at the Institute of Oncology “Prof.Dr.Alexandru Trestioreanu” Bucharest.